TY - JOUR
T1 - Bisphosphonate inhibitors of ATP-mediated HIV-1 reverse transcriptase catalyzed excision of chain-terminating 3′-azido, 3′-deoxythymidine
T2 - A QSAR investigation
AU - Song, Yongcheng
AU - Chan, Julian M.W.
AU - Tovian, Zev
AU - Secrest, Aaron
AU - Nagy, Eva
AU - Krysiak, Kilannin
AU - Bergan, Kyle
AU - Parniak, Michael A.
AU - Oldfield, Eric
N1 - Funding Information:
This work was supported by the United States Public Health Service (NIH Grants AI-060452 and AI-052010 to M.A.P., GM-073216 to E.O.). Y.S. was supported by a Leukemia and Lymphoma Society Special Fellowship. J.M.W.C. was a Jean Dreyfus Boissevein Fellow.
PY - 2008/10/1
Y1 - 2008/10/1
N2 - We report the results of an investigation of the inhibition of the ATP-mediated HIV-1 reverse transcriptase catalyzed phosphorolysis in vitro of AZT from AZT-terminated DNA primers by a series of 42 bisphosphonates. The four most active compounds possess neutral, halogen-substituted phenyl or biphenyl sidechains and have IC50 values <1 μM in excision inhibition assays. Use of two comparative molecular similarity analysis methods to analyze these inhibition results yielded a classification model with an overall accuracy of 94%, and a regression model having good accord with experiment (q2 = 0.63, r2 = 0.91), with the experimental activities being predicted within, on average, a factor of 2. The most active species had little or no toxicity against three human cell lines (IC50avg > 200 μM). These results are of general interest since they suggest that it may be possible to develop potent bisphosphonate-based AZT-excision inhibitors with little cellular toxicity, opening up a new route to restoring AZT sensitivity in otherwise resistant HIV-1 strains.
AB - We report the results of an investigation of the inhibition of the ATP-mediated HIV-1 reverse transcriptase catalyzed phosphorolysis in vitro of AZT from AZT-terminated DNA primers by a series of 42 bisphosphonates. The four most active compounds possess neutral, halogen-substituted phenyl or biphenyl sidechains and have IC50 values <1 μM in excision inhibition assays. Use of two comparative molecular similarity analysis methods to analyze these inhibition results yielded a classification model with an overall accuracy of 94%, and a regression model having good accord with experiment (q2 = 0.63, r2 = 0.91), with the experimental activities being predicted within, on average, a factor of 2. The most active species had little or no toxicity against three human cell lines (IC50avg > 200 μM). These results are of general interest since they suggest that it may be possible to develop potent bisphosphonate-based AZT-excision inhibitors with little cellular toxicity, opening up a new route to restoring AZT sensitivity in otherwise resistant HIV-1 strains.
KW - Bisphosphonate
KW - Nucleoside reverse transcriptase inhibitor (NRTI)
KW - Quantitative structure-activity relationship (QSAR)
KW - Reverse transcriptase
UR - http://www.scopus.com/inward/record.url?scp=52949106460&partnerID=8YFLogxK
U2 - 10.1016/j.bmc.2008.08.047
DO - 10.1016/j.bmc.2008.08.047
M3 - Article
C2 - 18789701
AN - SCOPUS:52949106460
SN - 0968-0896
VL - 16
SP - 8959
EP - 8967
JO - Bioorganic and Medicinal Chemistry
JF - Bioorganic and Medicinal Chemistry
IS - 19
ER -